Health Secretary Robert F. Kennedy Jr. told The New York Times that he personally instructed the U.S. Centers for Disease Control and Prevention to revise its long-standing message that vaccines do not cause autism. His disclosure, published Friday, confirms who was behind the surprising shift that caught many current and former CDC employees off guard earlier in the week.

Kennedy, who has a long history of opposing routine vaccination, has increasingly unsettled the public health agencies he now leads. His recent moves have raised concerns across the medical community, which sees many of his decisions as placing Americans at risk.

CDC Website Autism Vaccine Claim: What Kennedy Said and What Changed

In the interview, Kennedy dismissed the CDC’s previous guidance, calling the agency’s long-held position on vaccine safety “a lie.” The CDC’s updated “vaccine safety” page now argues that the statement “vaccines do not cause autism” cannot be proven with absolute certainty and implies that officials have disregarded research that hints at a possible link, as per CNN.

This new language conflicts with decades of scientific evidence and goes against the consensus view shared by independent researchers, pediatric groups and global health authorities.

How the Scientific Community Responded

Public health experts reacted sharply, warning that the revisions distort how evidence is evaluated in science. Researchers emphasized that while science cannot prove a negative, extensive data can rule out likely causes, and that is what has happened in the case of vaccines and autism, as per CNN.

Autism advocacy groups called the claim misleading. The Autism Science Foundation repeated that vaccines remain one of the most thoroughly investigated environmental factors linked to autism and that research across many countries and large populations has consistently found no association.

What the Science Actually Shows About Vaccines and Autism

Scientists have studied vaccines and autism for more than two decades. Large population studies in the United States, Europe and Asia have looked at the measles, mumps and rubella (MMR) vaccine, thimerosal-containing vaccines, and the timing of childhood immunization. Each line of research has reached the same conclusion: vaccines do not cause autism.

These findings have come from independent academic teams, government-funded studies and international health agencies, using different methods, age groups and datasets. Experts say the updated CDC wording misrepresents this evidence and may create unwarranted fear among parents, as per CNN.

A Promise Broken

Kennedy had previously assured Sen. Bill Cassidy, who chairs the Senate health committee, that he would keep the statement “vaccines do not cause autism” on the CDC website during his confirmation process. While the line remains, it now appears with a disclaimer noting that it was kept there specifically because of their agreement.

Cassidy said he opposed the update after Kennedy informed him of the change. The senator later warned that parents need clear reassurance, not confusion, especially on diseases like measles, polio and hepatitis B, where vaccination is proven to prevent severe illness.

A Wider Pattern of Disruption

The CDC website change is only one part of a broader shift under Kennedy’s leadership. He has withdrawn half a billion dollars from vaccine development initiatives, removed every member of a federal vaccine advisory panel, and signaled plans to overhaul the national vaccine injury compensation program.

He also dismissed former CDC Director Susan Monarez within weeks of her appointment after policy disagreements.

RFK Jr. Claims About The Vaccine Has Growing Distrust Within Medicine

Leaders in pediatrics and infectious disease warned Thursday that the new website language fuels misinformation rather than clarifying public health advice. Dr. Sean O’Leary of the American Academy of Pediatrics called the change “madness” and said it undermines confidence in the nation’s most basic health protections.

The Department of Health and Human Services did not respond to requests for comment.

A new study has discovered that use of antibiotics during pregnancy may raise the risk of babies developing Group B Streptococcus (GBS) disease.

Researchers from Sweden's Karolinska Institutet in Sweden and University of Antwerp in Belgium found prenatal antibiotic exposure to be associated with an increased risk of neonatal GBS disease by about 30 percent within four weeks of delivery. Exposure during early third trimester made the newborns most susceptible.

They scientists noted, "Prenatal antibiotic exposure can raise GBS risk within four weeks postpartum, especially in neonates not covered by risk-based intrapartum prophylaxis, with the early third trimester being a critical window of susceptibility."

What Is Group B Streptococcus (GBS) disease?

Most babies born to women carrying group B strep in their body are health but the few who are infected during labor can become very ill. The illness caused by group B strep can start within six hours of birth (early-onset disease) or three weeks after birth (late-onset disease).

Common symptoms include:

• Fever.
• Low body temperature.
• Trouble feeding.
• Sluggishness, limpness or weak muscle tone.
• Trouble breathing.
• Irritable behavior.
• Jittery movements.
• Seizures.
• Rash.
• Jaundice.

Universal prenatal screening around 36-37 weeks of pregnancy can help prevent the development of GBS disease in babies. The illness is typically treated with antibiotics.

What Did The Study Find?

The researchers conducted a population-based cohort study on 1,095,644 singleton live births in Sweden from 2006 to 2016 using national registers.

Among those, prenatal antibiotic exposure was recorded in 24.5 percent, of which 4.9 percent were exposed in more than one trimester. During the study period, the overall incidence of GBS disease was 0.71 per 1,000 live births.

Compared with unexposed newborns, GBS incidence within four weeks postpartum was higher among exposed newborns (0.86 per 1,000 live births) for an increased risk of 29%.

Among pregnancies without any GBS risk factors, prenatal antibiotic exposure was associated with a 34% higher risk of GBS disease.

Despite clear results, the authors noted it’s too early to draw causal conclusions more research into the links between antibiotics and GBS disease development is needed.

The researchers said, "Given the widespread use of antibiotics during pregnancy (~25% of pregnancies globally), rising GBS resistance, and the lack of licensed maternal GBS vaccine, this potential association warrants further studies."

This study was published in January 2026 in Journal of Infection.

In a recent episode of Soha Ali Khan’s YouTube podcast 'All About Her', actor Bhumi Pednekkar clarified that she has not used any weigh-loss drugs or injectables to lose over 40kgs of weight and credited her transformation to a balanced lifestyle.

The Dum Laga Ke Haisha star told Khan, "People have even asked me if I’ve had a rib removed. What about the fact that I’ve put 10 years into working out and eating right? In Delhi, women straight up come to me and ask, ‘Aapne bhi Ozempic ya Mounjaro liya hai?’

"I know enough people who have taken Ozempic and genuinely needed that medical assistance, so I will never judge anyone for it. But the fact is, I lost 40 kg and more without injectables.”

Pednekkar, 36, went on to also express annoyance over the rumors of her weight loss and noted that her battle against dengue in 2023 forced her to lose 12kgs.

"So basically, for this other character, I lost a lot of weight. I was in hospital recovering from dengue. I lost 12 kg and half my hair. The pain you go through is unmatched. It was Diwali and people were bursting crackers, while I had a splitting headache until I reached the hospital," she said.

How did Pednekkar lose weight?

For her workouts, she likes to mix things up with different workouts such as Pilates, running, strength training and weight training and completes nearly 8,000 steps on average every day.

What Are Ozempic and Mounjaro?

Ozempic (semaglutide) is a prescription injectable GLP-1 medication primarily approved for adults with Type 2 diabetes to manage blood sugar levels. However, the drug has gained immense popularity among those trying to lose weight as it can reduce hunger and help people feel full for longer, which forces the body to burn fat deposits to stay functional.

In clinical trials, people with obesity using semaglutide have shown to lose an average of about 15% of their body weight over 68 weeks. Most people begin to see noticeable results within 8 to 12 weeks of taking the drug.

The official price in India for a once-weekly Ozempic injection pen ranges from approximately ₹8,800 for the 0.25 mg dose to around ₹11,175 for the 1 mg dose per month. Insurance coverage is generally inconsistent for weight loss indications.

Similarly to Ozempic, Mounjaro mimics two natural gut hormones, GLP-1 and GIP, to regulate blood sugar, reduce appetite, slow digestion and provide the body with a feeling of fullness, leading to reduced calorie intake.

Clinical trials have shown that participants using Mounjaro along with lifestyle changes can lose up to 15-22% of their body weight over the span of 72 weeks.

Eli Lilly launched Mounjaro in India in March 2025 in the form of vials and released KwikPen versions of the drug later in August 2025. Monthly costs for KwikPens range from approximately ₹14,000 to ₹27,500.

Common side effects of both weigh-loss drugs include gastrointestinal issues, nausea, vomiting, diarrhea and constipation. More serious but rare side effects can include pancreatitis and gallbladder issues.

Typhoid fever, to many sound like it now belongs to history books, but a new strain that can resist strongest of antibiotics have emerged in South Asia. This has raised the concerns over the potential spread of drug-resistant infections.

A gene, which is capable of breaking down carbapenems, which is a powerful antibiotics was seen as a drug of last resort, is discovered among 32 samples collected from hospitals, across western and southern India. This gene is known as blaNDM-5, which can move between different types of bacteria, raising fears that resistance could in fact grow quickly.

Recent outbreaks of extensively drug-resistant (XDR) typhoid across South Asia have raised serious concerns, as these strains no longer respond to most commonly used antibiotics. Since 2016, Pakistan alone has reported over 15,000 XDR typhoid cases, while resistance to azithromycin has been detected in Bangladesh, India, Nepal and other neighboring regions.

Speaking to the Telegraph, Dr Malick Gibani, Clinical Lecturer in Infectious Diseases at Imperial College London, said, “We all hear that antimicrobial resistance is a problem, but typhoid really exemplifies it – how resistance seems to emerge relentlessly, moving from one class of antibiotics to the next."

“It’s not yet untreatable, but the treatments we do have are much more limited and significantly more challenging to deliver.”

What Is Typhoid?

Typhoid is caused by the bacteria Salmonella Typhi. It usually spreads through contaminated food or water and can lead to high fever, stomach pain and serious complications if not treated on time.

Antibiotics are the first line of treatment. These range from commonly used medicines such as amoxicillin and co-trimoxazole to stronger, hospital-only drugs for resistant infections, including carbapenems. Without timely treatment, typhoid can turn life-threatening and, in some cases, prove fatal. What has alarmed researchers is the emergence of typhoid strains that can resist even carbapenems.

“Although the number of cases described is still relatively small, this feels very much like a warning sign,” said Dr Gibani. “This was always expected and reflects the steady evolution of antimicrobial resistance in typhoid. These infections are not untreatable yet, but they are becoming increasingly difficult to manage.”

Experts point out that typhoid is often difficult to diagnose. This uncertainty can lead to the widespread and sometimes unnecessary use of antibiotics, which further fuels resistance. There are also concerns that extensively drug-resistant typhoid may be more widespread than current data suggests, especially in low-income countries where surveillance and reporting are limited.

“The risk is highest in places with poor water quality, uncontrolled antibiotic use and weak healthcare systems,” said Prof Calman A. MacLennan from the University of Oxford. He noted that while current typhoid mortality is under one percent, the disease was far deadlier before antibiotics were available. “In the pre-antibiotic era, death rates were as high as 10 to 20 percent, and during some wars, more people died of typhoid than from combat.”

Best Line Of Defense Against Typhoid

Vaccination, experts say, could be key to preventing a resurgence. The Typhoid Conjugate Vaccine, or TCV, has shown strong effectiveness by triggering the body’s immune response rather than targeting the bacteria directly with antibiotics. “That makes it much harder for the pathogen to escape,” Prof MacLennan explained.

The vaccine has already been introduced into national immunization programmes in 11 countries. However, reaching the poorest regions, where typhoid is most common, remains a challenge. Rolling out a new vaccine requires significant planning and resources, even with international support.

Dr Gibani warned that although South Asia has been hit hardest so far, drug-resistant typhoid can spread globally through travel. Imported cases have already been reported in Europe, North America and Australia. Experts stress that surveillance, vaccination and better sanitation are critical to stopping these dangerous strains from taking hold elsewhere.